Please sign in to follow a disease.
Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 452 of 6351
-
Can Stage-Based herbal therapy slow Alzheimer's decline?
Knowledge-focused Recruiting nowThe goal of this observational study is to learn how Alzheimer's disease changes over time in people at different stages of the disease. It will look at changes in memory and thinking, daily activities, behavior, and traditional Chinese medicine symptom patterns. It will also lea…
Sponsor: Dongzhimen Hospital, Beijing • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Could herbal pills cut eye injections for wet AMD? new trial launches
Disease control Not yet recruitingThe purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New HPV vaccine trial aims to protect kids and teens from cancer
Vaccine Recruiting nowThis is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9- and 15-month-olds) comparing them to an immune-bridg…
Phase 2 • Sponsor: International Vaccine Institute • Aim: Vaccine
Last updated Jun 27, 2026 12:34 UTC
-
AI and DNA test may boost IVF success for older women
Disease control Not yet recruitingBackground: Morphology-based embryo selection cannot detect aneuploidy, which is common in advanced maternal age and recurrent pregnancy loss. NICS-AI combines non-invasive chromosome screening (NICS) of cell-free DNA from spent blastocyst culture medium with AI integration of de…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for elderly lymphoma patients: targeted combo aims to control aggressive cancer
Disease control Recruiting nowEfficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
Phase 2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo attack on rare blood cancer shows promise in early trial
Disease control Recruiting nowThis is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radioth…
Phase 1/2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart insulin pump aims to simplify diabetes management
Disease control Recruiting nowA multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and sec…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
AI vs. drug: can a smart lifestyle program replace Weight-Loss shots?
Disease control Not yet recruitingThis is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance. The study consists of two phases: a 20-week lead-in phase, during which all participants will receive weekly subcutaneous t…
Phase 4 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug aims to slow Alzheimer's in chinese patients
Disease control Recruiting nowThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New ALS drug targets genetic cause in early human trial
Disease control Recruiting nowThis study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug)…
Phase 1/2 • Sponsor: Leal Therapeutics, Inc • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
AI scribes: the new tool to fight doctor burnout?
Symptom relief OngoingThe primary objective of the study is to investigate the impact of an ambient AI scribe on clinicians' wellness and well-being outcomes; additionally, the investigators will also explore how the use of the ambient AI scribe will lead to changes in documentation burden, clinical n…
Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Heart failure patients may skip some office visits with new remote monitoring
Disease control Recruiting nowThis randomized, multicenter clinical trial will evaluate whether remote management guided by the HeartLogic™ algorithm improves outcomes compared with traditional face-to-face follow-up in adult patients with heart failure recently implanted with a HeartLogic™-enabled ICD or CRT…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for stem cell patients: drug may stop debilitating chronic GVHD
Prevention Recruiting nowThis phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT). Allogeneic HCT is the most effective therapy for patients with hig…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jul 15, 2026 00:00 UTC
-
Fat infusions could help preterm babies breathe easier and develop better
Disease control Recruiting nowThe purpose of this study is to identify survival free of bronchopulmonary dysplasia (BPD), fatty acid profiles, and early biochemical measures for oxidative stress comparing mixed oil lipid emulsion (MOLE) vs soybean oil-based lipid emulsion (SOLE) and to establish whether MOLE …
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new vaccine stop a Lesser-Known bacterial threat?
Vaccine OngoingThis study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial. The study will include healthy adults between the ages of 18 and 65. Participants will be randomly assigned to …
Phase 2 • Sponsor: InventVacc Biologicals Inc. • Aim: Vaccine
Last updated Aug 05, 2026 00:00 UTC
-
Poop pills could save lives after stem cell transplants
Disease control Recruiting nowAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD), particularly acute gastrointestinal GvHD (GI-GvHD). …
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo aims to keep leukemia in check after remission
Disease control Not yet recruitingThis is a prospective, multicenter, randomized, open-label, phase III trial evaluating the efficacy and safety of azacitidine plus venetoclax versus azacitidine alone as maintenance therapy in patients with acute myeloid leukemia (AML) who have achieved first complete remission (…
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for kidney cancer: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respective…
Phase 2 • Sponsor: Brian Rini • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for lung cancer: experimental drug SHR-1826 enters phase 2 trial
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via int…
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowPSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic castrati…
Phase 2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC